RxDoctor Payments Data

Cynthia Brindle

Psychiatric/Mental Health · Richmond, INNPI 1841880507

Payments from drug & device makers

$2,784in general payments, 2019–2025

Across 183 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$940
  • Vanda Pharmaceuticals Inc.$280
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233
  • Johnson & Johnson$210
  • Otsuka America Pharmaceutical, Inc.$156
  • Teva Pharmaceuticals USA, Inc.$138
  • plus $828 from 14 others

What the payments were for

  • Food & beverage$2,72498%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,784 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$28,590
Medicare patients
75
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate30$105,280
AustedoDeutetrabenazine13$93,117
VraylarCariprazine Hcl40$58,085
TrintellixVortioxetine Hydrobromide21$10,870
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$6,104
Lurasidone Hcl40$5,423
Aripiprazole74$4,177
Venlafaxine Hcl ErVenlafaxine Hcl67$4,141
Vilazodone Hcl25$3,276
Quetiapine Fumarate103$2,892
Quetiapine Fumarate ErQuetiapine Fumarate18$2,786
Duloxetine Hcl152$2,473
Risperidone OdtRisperidone14$2,414
Ziprasidone Hcl38$2,131
Trazodone Hcl180$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$210$105,28030 claims
Teva Pharmaceuticals USA, Inc.Austedo$138$93,11713 claims
AbbVieVraylar$940$58,08540 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$97$10,87021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →